Michal Yalon-Oren

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial

Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren et al. · The Lancet Oncology · 2019 · 324 citations

Interim Analysis, Lymphoid Neoplasia, Surgical Oncology +10

Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency

Anirban Das, Sumedha Sudhaman, Daniel A. Morgenstern et al. · Nature Medicine · 2022 · 132 citations · Full text

DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells

Jiil Chung, Yosef E. Maruvka, Sumedha Sudhaman et al. · Cancer Discovery · 2020 · 84 citations · Full text

Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study

Sara Khan, Palma Solano‐Páez, Tannu Suwal et al. · The Lancet Child & Adolescent Health · 2021 · 39 citations

Multi-layered Rosettes, Neuro-oncology, Tumoral Pathology +11

Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1⁺ advanced, relapsed, or refractory solid tumor or lymphoma.

Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren et al. · Journal of Clinical Oncology · 2017 · 13 citations

Pathology, Immunotherapy, Refractory Solid Tumor +20